Klin Padiatr, 2017

High-throughput sequencing for diagnostics of minimal residual disease in acute lymphoblastic leukemia

Diagnostics of minimal residual disease (MRD) is the most powerful prognostic tool in acute lymphoblastic leukemia. MRD testing allows to determine risk of relapse and guides treatment decision. Here we describe a new method for MRD detection based on targeted high-throughput sequencing (HTS) of rearranged immunoglobulin genes specific for leukemic clones.

Komkov A, Miroshnichenkova A, Minervina A, Nugmanov G, Lebedev Y, Mamedov I, Olshanskaya Y, Maschan M

Laboratory of comparative and functional genomics

: 10.1055/s-0037-1602224
IBCH: 7317
Ссылка на статью в журнале: https://www.thieme-connect.de/DOI/DOI?10.1055/s-0037-1602224
Нет данных о цитировании
Данные статьи проверены модераторами 2017-05-30

Список научных проектов, где отмечена публикация

  1. Study of clonal variability of leukemic cells in acute lymphoblastic leukemia using massive sequencing of rearrangements of T- and B-cell receptor genes (June 30, 2017 — June 30, 2019). Komkov A.Y.. Grant, RSF.